Indinavir hæmmer CYP3A4 og forventes derfor at øge plasmakoncentrationen af de HMG- CoA- reduktasehæmmere markant, som er yderst afhængige af CYP3A4 - metabolismen.
Indinavir inhibits CYP3A4 and as a result is expected to markedly increase the plasma concentrations of these HMG-CoA reductase inhibitors, which are highly dependent on CYP3A4 metabolism.